



**FOR IMMEDIATE RELEASE**

**Chad Decker**  
Quad Technologies  
+1.484.280.2759  
Cdecker@quadtechnologies.com

## Quad Technologies patents novel T-cell activation reagent for CAR-T cell manufacturing

**Woburn, MA, October 18, 2017:** [Quad Technologies](#), a leader in cell and gene therapy bioprocessing reagents, announced today the U.S. Patent and Trademark Office has awarded the company a new U.S. Patent, No. 9,790,467, titled “Methods and Compositions for activation or expansion of T lymphocytes”. According to Quad Technologies CEO Sean Kevlahan, the patent relates to a scalable T-lymphocyte culture reagent that helps streamline CAR-T by eliminating the need for magnetic beads and the downstream “debeading” unit operation.

“Developing novel, innovative processes and reagents for cell and gene therapy is what we do,” Kevlahan said. “This patent strengthens Quad’s position in CAR-T to enable a critical unit of operation for T-cell activation and expansion without magnetic particles. This expansion of QuickGel™ highlights our dedication to improve bioprocessing technology and provide tools for non-magnetic workflows in today’s evolving marketplace.”

Traditional T-cell activation relies on magnetic particles, and the imperfect process of removing those particles downstream results in cellular product loss, additional qualification steps and increased operator time. Quad Technologies improves this process by employing a biocompatible dissolvable polymer technology called QuickGel™, which activates and expands T-cells without the need for magnetic de-beading. Quad Technologies has the ability to customize co-stimulatory ligands to help drive T-cell phenotype and transduction efficiency, as well as decreasing culture times.

According to the company, the patent comes just as there is a growing need in the industry for non-magnetic workflows.

### **About Quad Technologies:**

Woburn, Massachusetts-based Quad Technologies is a privately held company that develops bioprocessing reagents for cell-based therapeutics. Since the company’s founding in 2013 it has been hailed as a technical innovator and has operated on a process-centric basis. Our belief is that the end-user process is the product, and so we design our reagents to eliminate steps and create quality cells, producing better, more efficient therapeutic products. For more information, visit [www.quadtechnologies.com](http://www.quadtechnologies.com).